UB Paderborn / Katalog / Suche / in CDI

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

Annals of oncology, 2019-08, Vol.30 (8), p.1304-1310

2019

Volltextzugriff (PDF)

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Cancer chemotherapy and pharmacology, 2016-08, Vol.78 (2), p.369-376

2016

Volltextzugriff (PDF)

Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant

Antimicrobial Agents and Chemotherapy, 1997-04, Vol.41 (4), p.838-840

1997

Volltextzugriff (PDF)

Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be

Antimicrobial Agents and Chemotherapy, 1997-02, Vol.41 (2), p.475-477

1997

Volltextzugriff (PDF)

Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2)

Antimicrobial Agents and Chemotherapy, 1996-07, Vol.40 (7), p.1736-1740

1996

Volltextzugriff (PDF)

Clinicopathological characteristics and BRCA1/2 mutation rate in male breast cancer: a retrospective case series by the Hellenic Society of Medical Oncology

Annals of oncology, 2016-10, Vol.27, p.vi50-vi50

2016

Volltextzugriff (PDF)

Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: a multicentre, phase 2 study by the Hellenic Oncology Research Group

Annals of oncology, 2016-10, Vol.27, p.vi62-vi62

2016

Volltextzugriff (PDF)

Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study

Annals of oncology, 2016-10, Vol.27, p.vi221-vi221

2016

Volltextzugriff (PDF)

Characterization of a novel SHV β-lactamase variant that resembles the SHV-5 enzyme

FEMS microbiology letters, 1996-06, Vol.139 (2), p.229-234

1996

Volltextzugriff (PDF)

Epstein-Barr Virus Latent Membrane Protein 1 Activation of NF-κB through IRAK1 and TRAF6

Proceedings of the National Academy of Sciences - PNAS, 2003-12, Vol.100 (26), p.15595-15600

2003

Volltextzugriff (PDF)

Sporadic Emergence of Klebsiella pneumoniae Strains Resistant to Cefepime and Cefpirome in Greek Hospitals

Journal of Clinical Microbiology, 1998-01, Vol.36 (1), p.266-268

1998

Volltextzugriff (PDF)

In vitro activity of loracarbef against TEM extended-spectrum β-lactamase-producing Escherichia coli strains and its interaction with the enzymes

Chemotherapy (Basel), 1998-07, Vol.44 (4), p.260-264

1998

Volltextzugriff (PDF)

Characterization of a novel SHV α-lactamase variant that resembles the SHV-5 enzyme

FEMS microbiology letters, 1996-06, Vol.139 (2-3), p.229-234

1996

Volltextzugriff (PDF)

235 The use of a novel chromatographic molecular method for the detection of the membrane cancer antigen Ep-CAM (17-1A) in peripheral blood and bone marrow of patients with metastatic colorectal cancer

European journal of cancer supplements, 2003-09, Vol.1 (5), p.S73-S73

2003

Volltextzugriff (PDF)

In vitro Activity of Loracarbef against TEM Extended-Spectrum [beta]-Lactamase-Producing Escherichia coli Strains andIts Interaction with the Enzymes

Chemotherapy (Basel), 1998-07, Vol.44 (4), p.260

1998

Volltextzugriff (PDF)

Characterization of a novel SHV β‐lactamase variant that resembles the SHV‐5 enzyme

FEMS microbiology letters, 1996-06, Vol.139 (2‐3), p.229-234

1996

Volltextzugriff (PDF)

Characterization of a novel SHV Î²-lactamase variant that resembles the SHV-5 enzyme

FEMS microbiology letters, 1996-06, Vol.139 (2-3), p.229-234

1996

Volltextzugriff (PDF)

Implications of KRAS status in first line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15521-e15521

2018

Volltextzugriff (PDF)

Salvage treatment of relapsed/refractory small cell lung cancer with pazopanib: A Hellenic Oncology Research Group’s (HORG) phase II study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8561-8561

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant

Comparative evaluation of the inhibitory activities of the novel penicillanic acid sulfone Ro 48-1220 against beta-lactamases that belong to groups 1, 2b, and 2be

Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2)

Clinicopathological characteristics and BRCA1/2 mutation rate in male breast cancer: a retrospective case series by the Hellenic Society of Medical Oncology

Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: a multicentre, phase 2 study by the Hellenic Oncology Research Group

Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study

Characterization of a novel SHV β-lactamase variant that resembles the SHV-5 enzyme

Epstein-Barr Virus Latent Membrane Protein 1 Activation of NF-κB through IRAK1 and TRAF6

Sporadic Emergence of Klebsiella pneumoniae Strains Resistant to Cefepime and Cefpirome in Greek Hospitals

In vitro activity of loracarbef against TEM extended-spectrum β-lactamase-producing Escherichia coli strains and its interaction with the enzymes

Characterization of a novel SHV α-lactamase variant that resembles the SHV-5 enzyme

235 The use of a novel chromatographic molecular method for the detection of the membrane cancer antigen Ep-CAM (17-1A) in peripheral blood and bone marrow of patients with metastatic colorectal cancer

In vitro Activity of Loracarbef against TEM Extended-Spectrum [beta]-Lactamase-Producing Escherichia coli Strains andIts Interaction with the Enzymes

Characterization of a novel SHV β‐lactamase variant that resembles the SHV‐5 enzyme

Characterization of a novel SHV Î²-lactamase variant that resembles the SHV-5 enzyme

Implications of KRAS status in first line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG)

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project

Salvage treatment of relapsed/refractory small cell lung cancer with pazopanib: A Hellenic Oncology Research Group’s (HORG) phase II study

The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients’ characteristics and safety analysis

Suchergebnisse filtern